Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

被引：0
|
作者：
Aseem Anand
Michael J. Morris
Steven M. Larson
David Minarik
Andreas Josefsson
John T. Helgstrand
Peter S. Oturai
Lars Edenbrandt
Martin Andreas Røder
Anders Bjartell
机构：
[1] Lund University,Department of Translational Medicine, Division of Urological Cancers
[2] Memorial Sloan Kettering Cancer Center,Department of Medicine
[3] Weil Cornell Medical College,Department of Radiology
[4] Memorial Sloan Kettering Cancer Center,Department of Radiation Physics, Skåne University Hospital
[5] Lund University,Department of Urology, Institute of Clinical Sciences
[6] Sahlgrenska Academy,Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet
[7] University of Copenhagen,Department of Clinical Physiology, Nuclear Medicine and PET
[8] Copenhagen University Hospital,Department of Nuclear Medicine
[9] Skåne University Hospital,Department of Urology
[10] Skåne University Hospital,undefined
来源：
EJNMMI Research | / 6卷
关键词：
Bone Scan Index (BSI); Imaging biomarker; Bone scan; Enzalutamide; Metastatic castration-resistant prostate cancer (mCRPC);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide
    Anand, Aseem
    Morris, Michael J.
    Larson, Steven M.
    Minarik, David
    Josefsson, Andreas
    Helgstrand, John T.
    Oturai, Peter S.
    Edenbrandt, Lars
    Roder, Martin Andreas
    Bjartell, Anders
    EJNMMI RESEARCH, 2016, 6
  • [2] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [3] Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients
    Anand, Aseem
    Tragardh, Elin
    Edenbrandt, Lars
    Beckman, Lars
    Svensson, Jan-Henry
    Thellenberg, Camilla
    Widmark, Anders
    Kindblom, Jon
    Ullen, Anders
    Bjartell, Anders
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (05) : 671 - 675
  • [4] Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Hoang, Anh
    Karlou, Maria
    Ashe, Robynne
    Tu, Shi Ming
    Aparicio, Ana
    Troncoso, Patricia
    Mohler, James
    Logothetis, Christopher J.
    EUROPEAN UROLOGY, 2015, 67 (01) : 53 - 60
  • [5] Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
    Jeong, Chang Wook
    Han, Jang Hee
    Kwon, Dong Deuk
    Joung, Jae Young
    Kim, Choung-Soo
    Ahn, Hanjong
    Hong, Jun Hyuk
    Kim, Tae-Hwan
    Chung, Byung Ha
    Jeon, Seong Soo
    Kang, Minyong
    Hong, Sung Kyu
    Jung, Tae Young
    Park, Sung Woo
    Yun, Seok Joong
    Lee, Ji Yeol
    Lee, Seung Hwan
    Kang, Seok Ho
    Kwak, Cheol
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 634 - 641
  • [6] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [7] Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer
    Anand, Aseem
    Morris, Michael J.
    Kaboteh, Reza
    Bath, Lena
    Sadik, May
    Gjertsson, Peter
    Lomsky, Milan
    Edenbrandt, Lars
    Minarik, David
    Bjartell, Anders
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (01) : 41 - 45
  • [8] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [9] Development of enzalutamide for metastatic castration-resistant prostate cancer
    Bhattacharya, Suman
    Hirmand, Mohammad
    Phung, De
    van Os, Steve
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
  • [10] Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer
    Mitsui, Yozo
    Shiina, Hiroaki
    Yamamoto, Yasushi
    Haramoto, Masuo
    Arichi, Naoko
    Yasumoto, Hiroaki
    Kitagaki, Hajime
    Igawa, Mikio
    BJU INTERNATIONAL, 2012, 110 (11B) : E628 - E634
12345